Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Sepracor gets go-ahead for U.S. clinical trials on (S)-oxybutynin

Dec. 6, 1996

Synsorb Pk licensed to major Japanese pharmaceutical company

Dec. 4, 1996

Chugai starts phase I clinical trials with phosphate binder

Dec. 4, 1996

Negative clinical results reported for aromatase inhibitor in BPH

Nov. 29, 1996

Kissei begins overseas development of BPH treatment agent

Nov. 21, 1996

Kyorin claims cholinergic agents

Nov. 21, 1996

Glaxo Wellcome claims 5alpha-reductase inhibitors for BPH

Nov. 19, 1996

OP-1 effective in renal failure

Nov. 15, 1996

Clinical trial program for RenaGel continues on schedule

Nov. 8, 1996

Synaptic, Merck extend BPH collaboration

Nov. 8, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.